ROYALDERM Agnieszka Nawrocka

The research at ROYALDERM Agnieszka Nawrocka concentrates on immune system diseases that affect the skin, especially chronic urticaria and its inducible forms. Studies are designed to compare new biologic agents with established therapies and to explore innovative treatment pathways for patients with inadequate response to antihistamines.

• Therapeutic equivalence investigations in chronic spontaneous urticaria
• Evaluation of novel BTK inhibitors for chronic inducible urticaria
• Safety and tolerability assessments of emerging biologics in urticaria

By focusing on these objectives, the site aims to broaden effective options for individuals living with chronic urticaria and improve overall disease management.

In the field of skin and connective tissue diseases, the centre targets moderate to severe plaque psoriasis, seeking to confirm long‑term safety and sustained efficacy of new therapeutic agents. The research emphasizes durability of response and integrates patient‑reported outcomes to enhance treatment relevance.

• Long‑term safety monitoring of innovative psoriasis biologics
• Assessment of durability of clinical response in plaque psoriasis
• Incorporation of quality‑of‑life measures in skin disease trials

Located in Warsaw, Poland, the facility leverages its expertise to advance therapeutic options for psoriasis patients and contribute to broader dermatologic care.